Læknablaðið - 01.04.2015, Blaðsíða 24

208 LÆKNAblaðið 2015/101
R A N N S Ó K N
Heimildir
1. Diagnostic and Statistical Manual of Mental Disorders. 5th
ed. American Psychiatric Association, Arlington VA 2013.
2. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-
Bueno A. Insomnia with objective short sleep duration is
associated with a high risk for hypertension. Sleep 2009;
32: 491-7.
3. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep
duration and all-cause mortality: a systematic review
and meta-analysis of prospective studies. Sleep 2010; 33:
585-92.
4. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki
M, Basta M, et al. Insomnia with short sleep duration and
mortality: the Penn State cohort. Sleep 2010; 33: 1159-64.
5. Stoller MK. Economic effects of insomnia. Clin Ther 1994;
16: 873-97.
6. Rosekind MR, Gregory KB. Insomnia risks and costs:
health, safety, and quality of life. Am J Manag Care 2010;
16: 617-26.
7. Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J.
The economic burden of insomnia: direct and indirect
costs for individuals with insomnia syndrome, insomnia
symptoms, and good sleepers. Sleep 2009; 32: 55-64.
8. Guidance on the use of zaleplon, zolpidem and
zopiclone for the short-term management of insomnia.
Technology appraisal 77. National Institute for Clinical
Excellence, London 2004. nice.org.uk/nicemedia/
live/11530/32845/32845.pdf – júní 2014.
9. Chambless DL, Hollon SD. Defining empirically suppor-
ted therapies. J Consult Clin Psychol 1998; 66: 7-18.
10. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological
interventions for insomnia: a meta-analysis of treatment
efficacy. Am J Psychiatry 1994; 151: 1172-80.
11. Edinger J, Wohlgemuth W, Radtke R, Marsh G, Quillian
R. Cognitive behavioral therapy for treatment of chronic
primary insomnia: a randomized controlled trial. JAMA
2001; 285: 1856-64.
12. Marcussen JM (Ed.). Health statistics for the Nordic
countries 2013. Nordic Medico-Statistical Committee,
Copenhagen 2013. nowbase.org/~/media/Projekt%20sites/
Nowbase/Publikationer/Helse/Health%20Statistics%20
2013.ashx - júní 2014.
13. Kripke DF. Chronic hypnotic use: deadly risks, doubtful
benefit. Sleep Med Rev 2000; 4: 5-20.
14. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE,
Kvale G, et al. Cognitive behavioral therapy vs. zopiclone
for treatment of chronic primary insomnia in older adults:
a randomized controlled trial. JAMA 2006; 295: 2851-8.
15. Edinger JD, Carney, CE. Overcoming insomnia: A cogni-
tive-behavioral therapy approach-therapist guide. Oxford
University Press, Inc., New York 2008.
16. Morin CM. Cognitive-behavioral approaches to the
treatment of insomnia. J Clin Psychiatry 2004; 65: 33-40.
17. Morin CM, Colecchi C, Stone J, Sood R, Brink D.
Behavioral and pharmacological therapies for late-life
insomnia: A randomized controlled trial. JAMA 1999;
281: 991-9.
18. Lög um sjúkratryggingar. althingi.is/lagas/nuna/2008112.
html – júní 2014.
19. Edinger JD, Means MK. Cognitive-behavioral therapy for
primary insomnia. Clin Psychol Rev 2005; 25: 539-58.
20. Biering P. Þjónusta og þjónustuþarfir geðfatlaðra í
dreifbýli á Íslandi. Rauði kross Íslands, Reykjavík 2005.
raudikrossinn.is/redcross/upload/files/pdf/thjonustu-
tharfir_dreifbyli.pdf – janúar 2015.
21. Ritterband LM, Thorndike FP, Gonder-Frederick LA,
Magee JC, Bailey ET, Saylor DK. Efficacy of Internet-based
behavioral intervention for adults with insomnia. Arch
Gen Psychiatry 2009; 66: 692-8.
22. Strom L, Pettersson R, Andersson G. Internet-based
treatment for insomnia: a controlled evaluation. J Consult
Clin Psychol 2004; 72: 113-20.
23. Vincent N, Lewycky S. Logging on for better sleep:
RCT of the effectiveness of online treatment for
insomnia. Sleep 2009; 32: 807-15.
24. Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell-
Carnahan L, Baum LD. Initial evaluation of an Internet
intervention to improve the sleep of cancer survivors with
insomnia. Psychooncology 2011; 21: 695-705.
25. Lancee J, van den Bout J, van Straten A, Spoormaker
VI. Internet-delivered or mailed self-help treatment for
insomnia? A randomized waiting-list controlled trial.
Behav Res Ther 2011; 50: 22-9.
26. Espie CA, Kyle SD, Williams C, Ong JC, Douglas NJ,
Hames P, et al. A randomized, placebo-controlled trial of
online cognitive behavioral therapy for chronic insomnia
disorder delivered via an automated media-rich web app-
lication. Sleep 2012; 35: 769-81.
27. Bastien CH, Morin CM, Ouellet MC, Blais FC, Bouchard S.
Cognitive-behavioral therapy for insomnia: Comparison
of individual therapy, group therapy, and telephone
consultations. J Consult Clin Psychol 2004; 72: 653-9.
28. Diagnostic and Statistical Manual of Mental Disorders.
4th ed., text revision. American Psychiatric Association,
Washington DC 2000.
29. Perlis ML, Jungquist C, Smith MT, Posner D. Cognitive
Behavioral Treatment of Insomnia: A Session-by-Session
Guide. Springer, New York 2005.
30. Lichstein KL, Durrence HH, Taylor DJ, Bush AJ, Riedel
BW. Quantitative criteria for insomnia. Behav Res Ther
2003; 41: 427-45.
31. Van Straten A, Cuijpers P. Self-help therapy for insomnia:
a meta-analysis. Sleep Med Rev 2009; 13: 61-71.
32. Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effec-
tiveness of cognitive behaviour therapy in the treatment
of chronic insomnia: implementation and evaluation of a
sleep clinic in general medical practice. Behav Res Ther
2001; 39: 45-60.
33. Carney C, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal
AD, Lichstein KL, et al. The consensus sleep diary: stand-
ardizing prospective sleep self-monitoring. Sleep 2012;
35: 287-302.
34. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation
of chronic insomnia. Sleep 2000; 23: 243-63.
35. Morin CM, Bastien C, Savard J. Current status of
cognitive–behavior therapy for insomnia: Evidence for
treatment effectiveness and feasibility. In: Perlis ML,
Lichstein KL, eds. Treating sleep disorders: Principles and
practice of behavioral sleep medicine. John Wiley & Sons,
New York 2003: 262-85.
ENgLISH SUMMArY
introduction: Insomnia is a common health problem with serious men-
tal and physical consequences as well as increased economical costs.
The use of hypnotics in Iceland is immense in spite of cognitive behavio-
ral therapy for insomnia (CBT-I) being recommended as the first choice
treatment of chronic insomnia. To meet the needs of more individuals
suffering from insomnia, online CBT-I was established at betrisvefn.is.
The objective of this research was to evaluate the effectiveness of this
internet-based CBT-I.
Material and methods: one hundred seventy-five users (mean age 46y
(18-79y)) started a 6 week online intervention for insomnia. The drop-
out rate was 29%, leaving a final sample of 125 users. The intervention
is based on well-established face-to-face CBT-I. Sleep diaries were
used to determine changes in sleep efficiency, sleep onset latency and
wake after sleep onset. Treatment effects were assesed after 6 weeks of
treatment and at the 6 week follow-up.
Results: Significant improvement was found in all main sleep variables
except for 5% decrease in total sleep time (TST). Effects were sustained
at 6 week follow-up and TST increased. The use of hypnotics decreased
significantly. This form of treatment seems to suit its users very well and
over 94% would recommend the treatment.
Conclusion: Internet interventions for insomnia seem to have good
potential. CBT-I will hopefully be offered as the first line treatment for
chronic insomnia in Iceland instead of hypnotics as the availability of the
CBT-I is growing. Thus, the burden on health care clinics might reduce
along with the hypnotics use and the considerable costs of insomnia.
Effectiveness of an online cognitive behavioral therapy for insomnia
Gudlaug Fridgeirsdóttir1, Steindor oddur Ellertsson2, Gunnar johannsson3, Erla Björnsdottir1,4
1University of Iceland, 2Primary Health Care of the Capital Area, 3Health Care Institution of the Westman Islands, 4The National University Hospital of Iceland.
key words: insomnia online CBT Internet treatment sleep.
Correspondence: Guðlaug Friðgeirsdóttir, guf11@hi.is
1) Brintellix (vortioxetín) samantekt á eiginleikum lyfsins, sjá www.serlyfjaskra.is.
2) Katona C et al. Int Clin Psychopharmacol. 2012; 27(4): 215-223.
3) McIntyre RS et al. Int. J. Neuropsychopharmacology 2014 doi:10. 1017/S1461145714000546.
4) Alvarez E et al. Int J Neuropsychopharmacol. 2012; 15(15): 589-600.
5) Baldwin DS et al. Eur Neuropsychopharmacol. 2012; 22(7): 482-491.
6) Boulenger JP et al. J Psychopharmacol. 2012; 26(11): 1408-1416.
IS
-B
R
IN
-2
01
4.
11
-0
00
01
50
4
Brintellix® (vortioxetín)
– nýtt þunglyndislyf með fjölþætta verkun til meðferðar á alvarlegum
þunglyndisköstum hjá fullorðnum1
Verkunarháttur1
Brintellix (vortioxetín) er nýtt þunglyndislyf með fjölþætta verkun.
Verkun1
Verkun Brintellix (vortioxetín) hefur verið rannsökuð samkvæmt klínískri áætlun með fleiri
en 6.700 sjúklingum.
Vitsmunaleg færni2,3
Brintellix (vortioxetín) bætir vitsmunalega færni marktækt samanborið við lyfleysu hjá
sjúklingum með alvarlegt þunglyndi (MDD).
Þolanleiki1,4,5,6
Brintellix (vortioxetín) þolist vel.
Skammtar1
Upphafs- og viðhaldsskammtur Brintellix (vortioxetín) er 10 mg einu sinni á dag fyrir fullorðna
yngri en 65 ára.
NÝJU
NG
Vistor hf Hörgatún 2 210 Garðabær
Sérlyfjatexti bls. 226